scispace - formally typeset
M

Melanie Greenland

Researcher at University of Oxford

Publications -  32
Citations -  2415

Melanie Greenland is an academic researcher from University of Oxford. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 10, co-authored 21 publications receiving 933 citations. Previous affiliations of Melanie Greenland include Churchill Hospital & University of Western Australia.

Papers
More filters
Journal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
Journal ArticleDOI

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Katherine R. W. Emary, +69 more
- 10 Apr 2021 - 
TL;DR: A post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against B.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020 as discussed by the authors.
Journal ArticleDOI

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Xinxue Liu, +90 more
- 04 Sep 2021 - 
TL;DR: The Com-COV trial as discussed by the authors evaluated vaccine safety, reactogenicity, and immunogenicity of the BNT/ChAd schedule with a 28-day or 84-day prime-boost interval.
Journal ArticleDOI

Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial

TL;DR: There is strong evidence to suggest that planned delivery reduces maternal morbidity and severe hypertension compared with expectant management, with more neonatal unit admissions related to prematurity but no indicators of greater neonatal morbidity.